Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare

被引:39
|
作者
Carubbi, Francesco [1 ]
Zugaro, Luigi [2 ]
Cipriani, Paola [1 ]
Conchiglia, Armando [2 ]
Gregori, Lorenzo [2 ]
Danniballe, Cristino [2 ]
Pistoia, Maria Letizia [1 ]
Liakouli, Vasiliki [1 ]
Ruscitti, Piero [1 ]
Ciccia, Francesco [3 ]
Triolo, Giovanni [3 ]
Masciocchi, Carlo [2 ]
Giacomelli, Roberto [1 ]
机构
[1] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Rheumatol Unit, Edificio Delta 6,Via Osped Snc, I-67100 Laquila, Italy
[2] Univ Aquila, Dept Radiol, I-67100 Laquila, Italy
[3] Univ Palermo, Dept Internal Med, Rheumatol Unit, Palermo, Italy
关键词
anti-tumor necrosis factor alpha agent; intra-articular injection; magnetic resonance imaging (MRI); psoriatic arthritis; rheumatoid arthritis; treat-to-target strategy; ultrasonography; REFERENCE IMAGE ATLAS; RHEUMATOID-ARTHRITIS; PSORIATIC-ARTHRITIS; TNF-ALPHA; SYNOVIAL-FLUID; CLASSIFICATION CRITERIA; DOUBLE-BLIND; INFLIXIMAB; ULTRASOUND; MRI;
D O I
10.1177/0394632015593220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in patients injected with anti-TNF alpha. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were considered secondary endpoints. Intra-articular TNF blockers are a safe strategy, determining a significant reduction of patient and physician reported clinical outcomes and US/MRI scores, in RA and PsA patients, when compared to intra-articular injections of corticosteroids. US guidance excluded the possibility to inject the drug in the wrong site, maximizing local effects, reducing systemic effects, and increasing the safety of the procedure. Patients with inflammatory monoarthritis could be successfully treated with US-guided intra-articular TNF blockers that are a safe and well tolerated procedure, to achieve a longstanding clinical and radiological good clinical response and/or disease remission.
引用
收藏
页码:252 / 266
页数:15
相关论文
共 50 条
  • [31] Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
    Kim, Ju Young
    Lee, Yoon
    Choe, Byung-Ho
    Kang, Ben
    GUT AND LIVER, 2021, 15 (04) : 588 - 598
  • [32] Anti-Tumor Necrosis Factor Agents Are Mostly Used in Patients with Established Rheumatoid Arthritis Compared to Early Disease - A Reflection of Adequate Clinical Practice
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (08) : 1561 - 1562
  • [33] Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease
    Kane, Sunanda V.
    Jaganathan, Srihari
    Bedenbaugh, Angela V.
    Palmer, Liisa
    Schwartz, David A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (09) : 1821 - 1826
  • [34] Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment
    Higashida, J
    Wun, T
    Schmidt, S
    Naguwa, SM
    Tuscano, JM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2109 - 2115
  • [35] B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
    Finckh, Axel
    Ciurea, Adrian
    Brulhart, Laure
    Kyburz, Diego
    Moeller, Burkhard
    Dehler, Silvia
    Revaz, Sylvie
    Dudler, Jean
    Gabay, Cem
    ARTHRITIS AND RHEUMATISM, 2007, 56 (05): : 1417 - 1423
  • [36] Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis
    Nagashima, Takao
    Okubo-Fornbacher, Hikaru
    Aoki, Yoko
    Kamata, Yasuyuki
    Kimura, Hirotaka
    Kamimura, Takeshi
    Nara, Hiroyuki
    Iwamoto, Masahiro
    Yoshio, Taku
    Okazaki, Hitoaki
    Minota, Seiji
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (05) : 936 - 938
  • [37] Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor α agents in rheumatoid arthritis
    Sokka, T
    Pincus, T
    ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 313 - 318
  • [38] Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study
    Yong Chen
    Jiali Yuan
    Zuli Cai
    Yan Ma
    Clinical Rheumatology, 2023, 42 : 1793 - 1799
  • [39] Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study
    Chen, Yong
    Yuan, Jiali
    Cai, Zuli
    Ma, Yan
    CLINICAL RHEUMATOLOGY, 2023, 42 (07) : 1793 - 1799
  • [40] Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents
    Hung-Viet Pham
    Hasan, Imran
    Udaltsova, Natalia
    Pham, Kathy
    Abramson, Oren
    Armstrong, Mary Anne
    Postlethwaite, Debbie
    Li, Dan
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (01) : 209 - 217